Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

VIVUS Announces Richard Fante, Former President U.S. and CEO North America, AstraZeneca, to Serve as Senior Advisor



VIVUS Announces Richard Fante, Former President U.S. and CEO North America,
AstraZeneca, to Serve as Senior Advisor

MOUNTAIN VIEW, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS) (the Company) today announced that Richard Fante, former
president U.S., CEO North America and regional vice president Americas at
AstraZeneca, has agreed to provide advisory services to the Company. In this
role, Mr. Fante will advise the Company regarding commercial options to access
the primary care market and maximize the value of Qsymia^® (phentermine and
topiramate extended-release) capsules CIV.

Mr. Fante has more than 20 years of experience in the pharmaceuticals sector.
He has an established track record of constructing and managing strong teams
and aligning large and small organizations to deliver results. His scope of
responsibilities has ranged from building iconic pharmaceutical brands to
leading an organization in excess of 7,000 employees and revenues of more than
$12 billion. Among his main accomplishments at AstraZeneca were establishing
Nexium^®, Crestor^® and Seroquel^® as three of the top 10 brands in the U.S.
through well-articulated brand strategies and focused marketing and sales
execution.

"We are excited to have an executive of Richard Fante's caliber advising VIVUS
at this critical time," commented Leland Wilson, chief executive officer of
VIVUS. "With the recent FDA approval of the REMS modification for Qsymia, and
more payors recognizing medical obesity treatment, VIVUS is making significant
progress on its commercialization strategies. Rich's vast experience and
unique perspectives building several primary care products into market-leading
brands will be extremely valuable as we seek to expand Qsymia's primary care
presence."

Mr. Fante began his pharmaceutical career as a sales representative. In 1995,
Mr. Fante joined AstraZeneca, where he rose through the commercial ranks and
was promoted to various senior management roles within the organization,
culminating in his appointment as president of the U.S. business in 2008 and
CEO for North America in 2009. In 2011, he assumed responsibility for Central
and South America. He holds a bachelor's degree in biology from Princeton
University and a master's in business administration from the University of
North Carolina.

About Qsymia

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet
and increased physical activity for chronic weight management in adults with
an initial body mass index (BMI) of 30 kg/m^2 or greater (obese) or 27 kg/m^2
or greater (overweight) in the presence of at least one weight-related medical
condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in
Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the
fetus.

The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health. For more information about the company,
please visit www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995 and are
subject to risks, uncertainties and other factors, including risks and
uncertainties related to the expansion of Qsymia's primary care presence and
our strategic and franchise-specific pathways for Qsymia. These risks and
uncertainties could cause actual results to differ materially from those
referred to in these forward-looking statements. The reader is cautioned not
to rely on these forward-looking statements. Investors should read the risk
factors set forth in VIVUS's Form 10-K for the year ending December 31, 2012,
as amended by the Form 10-K/A filed on April 30, 2013, and periodic reports
filed with the Securities and Exchange Commission. VIVUS does not undertake an
obligation to update or revise any forward-looking statements.

Important Additional Information

VIVUS, its directors and certain of its executive officers may be deemed to be
participants in the solicitation of proxies from VIVUS stockholders in
connection with the matters to be considered at VIVUS's 2013 Annual Meeting of
Stockholders. VIVUS intends to file a proxy statement with the U.S. Securities
and Exchange Commission (the "SEC") in connection with any such solicitation
of proxies from VIVUS stockholders. INVESTORS AND STOCKHOLDERS ARE STRONGLY
ENCOURAGED TO READ ANY SUCH PROXY STATEMENT AND ACCOMPANYING PROXY CARD AND
OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY
BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Information
regarding the identity of potential participants, and their direct or indirect
interests, by security holdings or otherwise, will be set forth in the proxy
statement and other materials to be filed with the SEC in connection with
VIVUS's 2013 Annual Meeting of Stockholders. Information regarding the direct
and indirect beneficial ownership of VIVUS's directors and executive officers
in VIVUS securities is included in their SEC filings on Forms 3, 4 and 5, and
additional information can also be found in VIVUS's Annual Report on Form 10-K
for the year ended December 31, 2012, filed with the SEC on February 26, 2013,
Amendment No. 1 to VIVUS's Annual Report on Form 10-K/A filed with the SEC on
April 30, 2013, and in VIVUS's definitive proxy statement on Schedule 14A in
connection with VIVUS's 2012 Annual Meeting of Stockholders, filed with the
SEC on April 25, 2012. Stockholders will be able to obtain any proxy
statement, any amendments or supplements to the proxy statement and other
documents filed by VIVUS with the SEC for no charge at the SEC's website at
www.sec.gov. Copies will also be available at no charge at the Investor
Relations section of VIVUS's corporate website at www.vivus.com.

CONTACT: VIVUS, Inc.
         Timothy E. Morris
         Chief Financial Officer
         morris@vivus.com
        
         Dana B. Shinbaum
         Corporate Development
         & Investor Relations
         shinbaum@vivus.com
        
         Investor Relations:
         The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923
        
         Morrow & Co., LLC
         Joseph J. Mills
         jmills@morrowco.com
         203-658-9423
        
         Media Relations:
         Joele Frank, Wilkinson Brimmer Katcher
         Matthew Sherman
         msherman@joelefrank.com
         212-355-4449
        
         Jennifer Beugelmans
         jbeugelmans@joelefrank.com
         212-355-4449
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement